Musely, a pioneering telemedicine platform focused on direct-to-consumer services, has successfully secured over $360 million in non-dilutive capital from General Catalyst's Customer Value Fund (CVF). This innovative financing approach allows Musely to enhance its offerings without sacrificing equity.
The company, which specializes in compounded treatments for skin, hair, and menopause care, was co-founded by CEO Jack Jia. Notably, Jia revealed to TechCrunch that he was not actively seeking investment when CVF approached him last year. Musely, established in 2014 as a wellness community and transitioning to prescription skincare in 2019, has maintained a positive cash flow for several years. Jia was hesitant to dilute his ownership by entertaining venture capital offers, which he frequently declined.
What sets CVF apart from traditional venture capital is its unique financing model. Rather than seeking an equity stake or offering a conventional loan with interest, CVF provides alternative funding through a revenue-share agreement. Companies with reliable revenue streams can borrow capital and repay it with a fixed, capped percentage of their revenue generated from using the fund. Initially skeptical, Jia quickly recognized that CVF's terms were more advantageous than a typical bank loan and significantly less costly than an equity round.
"When I mathematically modeled it, I found this absolutely compelling," Jia stated, highlighting the strategic benefits of this funding approach.
Musely has been experiencing remarkable growth, with revenue increasing by an average of 50% annually and serving over 1.2 million patients. However, acquiring new customers remains a costly endeavor for direct-to-consumer brands like Musely. "To grow from a billion-dollar revenue company to the next billion, you often need significant additional capital," Jia explained, noting the substantial capital burn many DTC companies face.
The funding from CVF addresses this challenge, equipping Musely with the necessary resources to bolster its customer acquisition strategies, including sales and marketing initiatives.
Musely joins a prestigious portfolio within CVF that includes notable companies such as Grammarly, Lemonade, and Ro. Importantly, the capital invested through CVF is distinct from General Catalyst's recent $8 billion fundraising efforts, showcasing its unique approach to supporting innovative startups.
Since its initial $20 million raise from DCM and other investors in 2014, Musely has not pursued any additional equity funding. The platform facilitates access to prescription products through asynchronous consultations with board-certified dermatologists and OB-GYNs, exemplifying a modern approach to healthcare.
This funding marks a significant milestone for Musely, positioning the company to further innovate and expand its impact in the telemedicine space, potentially reshaping how patients access specialized care in the future.
